Pharvaris N.V.
NASDAQ:PHVSBiotechnology
-$0.64 today
- Market cap
- $2.21B
- Beta
- -2.33
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.59
Volume 0.39M
Average 0.31M
PHVS Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Pharvaris N.V.NASDAQ: PHVS
Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026
Cost of revenue remains negative
Q3 FY2026 cost of revenue was €0, compared with €0 a year earlier. Trailing-twelve-month cost of revenue was €106.45K.
Context
- Cost of revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly cost of revenue holds near €0 or moves back toward the trailing-twelve-month quarterly average of €26.61K.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
EUR · from the income statement
- Latest · FY2025
- 0 EUR
- Year-over-year change
- —
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Cost of Revenue vs competitors
How PHVS compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +9.7% is the 5th highest of 6, against a peer median of +204.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $206.11B USD | +35566.9% | +13.6% | 20.1% | |
| LTM Jun 2026 | $719.42M USD | +4201.4% | +42.5% | 76.5% | |
| LTM Mar 2026 | $46.97M USD | +32.9% | +37.5% | 12.7% | |
| LTM Sep 2026 | $31.49M USD | +204.6% | +32.7% | 4.8% | |
| LTM Sep 2026 | €106.45K EUR | +9.7% | — | — | |
| LTM Mar 2026 | $67K USD | -46.0% | -18.0% | 7.8% | |
| LTM Jun 2026 | $0 USD | — | — | — | |
| Peer median (excluding PHVS) | — | +204.6% | +32.7% | 12.7% | |
Competitors are the stored peer set for PHVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 35.79M | 57.38M | 65.58M | 98.56M | 124.48M |
| Selling, General & Admin | 18.35M | 29.34M | 31.34M | 47.12M | 45.34M |
| Operating Expenses | 54.14M | 86.71M | 96.91M | 145.69M | 169.82M |
| Depreciation & Amortization | 77.37K | 152.94K | 257.55K | 269.56K | 418.35K |
| EBITDA | (42.31M) | (86.56M) | (99.57M) | (145.42M) | (173.29M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (54.14M) | (86.71M) | (96.91M) | (145.69M) | (169.82M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 268 | 16 | 0 | 5.47M | 0 |
| Interest Expense | 278.18K | 16.11K | 0 | 0 | 0 |
| Other Income / Expenses | 11.48M | 11.06M | (2.91M) | 13.29M | (3.89M) |
| Income Before Tax | (42.66M) | (75.65M) | (99.83M) | (132.4M) | (173.71M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 70.12K | 679.09K | 1.05M | 1.83M | 1.99M |
| Net Income | (42.73M) | (76.33M) | (100.88M) | (134.22M) | (175.7M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.41) | (2.27) | (2.63) | (2.48) | (2.97) |
| EPS (Diluted) | (1.41) | (2.27) | (2.63) | (2.48) | (2.97) |
| Weighted Avg Shares | 30.41M | 33.59M | 38.39M | 54.02M | 59.16M |
| Weighted Avg Shares (Diluted) | 30.41M | 33.59M | 38.39M | 54.02M | 59.16M |
Pharvaris N.V.
NASDAQ:PHVS
Intrinsic Alpha fair value
Locked
Current Price
$31.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.